Press Releases – CellCentric

Press and media

Press releases

More regular updates and key information, updates and news can be found on the CellCentric LinkedIn page.

CellCentric to Host Investor Event and Present Dose Optimization Data from Phase 2 Study of Inobrodib for Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting

3 November 2025 Press Release

CellCentric Announces Completion of Enrollment for Dose Optimization Cohorts in Phase 2 Study for Multiple Myeloma

9 September 2025 Press Release

CellCentric Announces First Patients Dosed with Inobrodib in Combination with Bispecific Antibodies in Multiple Myeloma

3 September 2025 Press Release

CellCentric to Participate in Upcoming Investor Conferences

5 August 2025 Press Release

CellCentric secures $120 million investment to advance inobrodib for treating multiple myeloma

19 May 2025 Press Release

cell-centric-expands-to-US-office-Boston

CellCentric Expands US Presence with New Office in Boston

2 April 2025 Press Release

CellCentric expands executive team with new Chief Strategy Officer

13 January 2025 Press Release

CellCentic Presents Latest Clinical Data at ASH: Promising Efficacy and Safety in Multiple Myeloma

10 December 2024 Press Release

CellCentric to Share Latest Inobrodib Phase II Data; Oral Presentation at ASH 2024

6 November 2024 Press Release

CellCentric Secures $35 Million Investment from RA Capital Management

24 July 2024 Press Release

CellCentric discloses significant new clinical data, demonstrating inobrodib’s efficacy in ongoing Phase I/IIa clinical trials

11 December 2023 Press Release

Inobrodib’s novel mechanism: new data published in Cancer Cell

22 November 2023 Press Release

Inobrodib

A first-in-class oral
anti-cancer drug